Colinz Laboratories

Colinz Laboratories Diluted EPS

The Diluted Earnings per Share of Colinz Laboratories (531210.BO) as of Oct 17, 2026 is 2.04 INR. In the previous year, Diluted Earnings per Share was 1.97 INR — a change of 3.60% (higher).

Diluted EPS

2.04INR

YoY

3.60%

Last updated:

Diluted Earnings per Share of Colinz Laboratories is 2026 2.04 INR. Diluted Earnings per Share of Colinz Laboratories was 2025 1.97 INR. It decreases by 3.60% higher compared to the previous year.

The Colinz Laboratories Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2019
0.48 INR
Jan 1, 2020
0.52 INR
Jan 1, 2021
0.82 INR
Jan 1, 2022
1.35 INR
Jan 1, 2023
1.82 INR
Jan 1, 2024
1.93 INR
Jan 1, 2025
1.97 INR
Jan 1, 2026
2.04 INR
The Colinz Laboratories Diluted EPS history
YEARDiluted EPSYoY
2.04INR+3.60%
1.97INR+2.03%
1.93INR+6.41%
1.82INR+34.81%
1.35INR+63.46%
0.82INR+59.13%
0.52INR+7.15%
0.48INR-47.22%
0.92INR+195.17%
0.31INR+49.92%
0.21INR-46.02%
0.38INR+45.21%
0.26INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd, listed on the Bombay Stock Exchange with ticker 531210.BO and ISIN INE923C01011, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It went public through an IPO on January 13, 2004. Colinz Laboratories is engaged in the manufacturing and marketing of pharmaceutical formulations across various dosage forms, including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company's product portfolio targets several medical conditions, such as hypertension, cholesterol, diabetes, piles, pyrexia, and malaria, with specific offerings for gynecological treatments like morning sickness, infertility, intrauterine growth restriction (IUGR), and pregnancy maintenance. Additionally, it provides hematinic, antispasmodic, anti-inflammatory, anti-allergic, and medicated shampoo products. Colinz Laboratories markets its products directly within several Indian states, including Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal, utilizing its own marketing team. The company's website is www.colinz.com. It is important to note that the company's operations and product details are based on the provided information without additional verification. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

Diluted Earnings per Share of Colinz Laboratories is 2.04 INR in 2026.

Diluted Earnings per Share of Colinz Laboratories changed from 1.97 INR to 2.04 INR, representing a 3.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Colinz Laboratories

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Colinz Laboratories